Text
Decisive next steps: fundraising, production of vaccine batches and first human trials
Founded by Isabelle Dimier-Poisson, head of the BioMAP research team behind the project, UMR ISP, and Patrick Barillot, former director of development at Recipharm, the start-up LoValTech (for Loire Valley Technology) has held since its creation in January 2022 an exclusive license to use the candidate vaccine, granted jointly by the University of Tours and INRAE. Mathieu Epardaud (INRAE researcher) and Nicolas Aubrey (research professor at the University of Tours), members of BioMAP, are also part of the adventure as partners and will be scientific consultants for the start-up. After aid of €500,000 received for the scientific development phase by the ANR and the Centre-Val-de-Loire region, an envelope of €2.4 million was allocated, including €1.5 million from the Ministry of Higher Education, Research and Innovation and 0.9 million euros by the ANRS | Emerging Infectious Diseases, at the University of Tours, in order to produce vaccine proteins in a GMP (Good Manufacturing Practice) environment essential for human trials. From the 1st quarter of 2022, the challenge will be to produce this biomedicine by the Toulouse company GTP Bioways and to launch the production of clinical batches in the 2nd quarter for human trials.
–
–
